Efficacy and safety of the all-oral regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in GT1 HCV/HIV co-infected patients: The c-worthy study

Authors
Category Primary study
JournalJournal of Hepatology
Year 2014
This article has no abstract
Epistemonikos ID: 1a15fdc5ec32d039a1197b88e793b5ae34fa1153
First added on: Dec 01, 2021